Recombinant Vaccines Market: By Type, By Route of Administration, By Disease Indication By Distribution Channel and Region Forecast 2019-2030

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Recombinant Vaccines Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Subunit and Live Attenuated), By Route of Administration (Parenteral and Oral), By Disease Indication (Human Papillomavirus, Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others) By Distribution Channel (Hospitals & Retail Pharmacies, Government Suppliers, and Others) and Region Forecast 2019-2030

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Recombinant Vaccines Market was estimated to be valued at US$ 11,507.3 million in 2023, and it is expanded to grow at a significant CAGR of 5.3% from 2024-2030. The main factors driving the global recombinant vaccine market are the full-fledged recombinant properties in providing the effectiveness and safety of the patient getting immunized. Additionally, the increasing prevalence of viral diseases in countries worldwide is anticipated to boost the market. The growing population and strict regulations for infant immunization are projected to drive the overall market. Another significant driving force is the improvement of technology in the fields of recombinant DNA technology, genetics, and proteomics, which is boosting vaccination R&D.

As a result, the number of clinical trials is increasing. Based on the Route of Administration, the parenteral segment has a significant share of the global market with a share of 87.3% in 2022 the global market and is projected to grow at 4.9% CAGR from 2023 - 2029. The parenteral vaccines, such as enhanced potency inactivated polio vaccine, Haemophilus influenzae type B, hepatitis B virus (HBV), and other non-mucosal vaccines, have been highly effective in preventing systemic disease during subsequent exposure to natural infection.

Key Developments:

  • In Jan 2021, Merck, a leading science and technology company, announced the acquisition of Amptek, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck's capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments, and diagnostics applicable in Covid-19 and many other diseases. Financial terms were not disclosed.
  • In April 2021, Sanofi and GSK announce that they have signed a letter of intent to enter collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.

summary download arrow Download Free Sample

Recombinant Vaccines Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.3%

Largest Market

North-America

Fastest Growing Market

Asia Pacific

Recombinant Vaccines Market Dynamics

The market for recombinant vaccines is predicted to develop as the incidence of zoonotic diseases rises, and new technologies emerge. Furthermore, the marketplace is likely to be fueled by continued investment in vaccine research and development and growing public awareness of vaccines. The high cost associated with recombinant vaccines would inhibit the market.

Recombinant Vaccines Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 11,507.3 million

Market CAGR

5.3%

By Type

  • Subunit
  • Live Attenuated

By Route Administration

  • Parenteral
  • Oral

By Disease Indication

  • Human Papillomavirus
  • Hepatitis B
  • Rotavirus
  • Herpes Zoster
  • Meningococcal B
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The recombinant vaccines market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The recombinant vaccines market size was valued at US$ 11,507.3 million in 2023 and is set to grow at a significant CAGR of 5.3% from 2024-2030.

Merck KGaA, Novartis AG, GlaxoSmithKline Plc., GC Biopharma, Bayer AG, Sanofi SA, Pfizer Inc.

The Asia Pacific is the fastest-growing region in the market

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Recombinant Vaccines Market Introduction 
2.1.Global Recombinant Vaccines Market  - Taxonomy
2.2.Global Recombinant Vaccines Market  - Definitions
2.2.1.Type 
2.2.2.Route Administration
2.2.3.Disease Indication
2.2.4.Region
3. Global Recombinant Vaccines Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Recombinant Vaccines Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Recombinant Vaccines Market  By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Subunit
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Live Attenuated
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6. Global Recombinant Vaccines Market  By Route Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Parenteral
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Oral
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7. Global Recombinant Vaccines Market  By Disease Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Human Papillomavirus
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Hepatitis B
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Rotavirus
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Herpes Zoster
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Meningococcal B
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
7.6. Others
7.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.6.3. Market Opportunity Analysis 
8. Global Recombinant Vaccines Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Recombinant Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Subunit
9.1.2.Live Attenuated
9.2.  Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Parenteral
9.2.2.Oral
9.3.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Human Papillomavirus
9.3.2.Hepatitis B
9.3.3.Rotavirus
9.3.4.Herpes Zoster
9.3.5.Meningococcal B
9.3.6.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Recombinant Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Subunit
10.1.2.Live Attenuated
10.2.  Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Parenteral
10.2.2.Oral
10.3.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Human Papillomavirus
10.3.2.Hepatitis B
10.3.3.Rotavirus
10.3.4.Herpes Zoster
10.3.5.Meningococcal B
10.3.6.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11. Asia Pacific (APAC) Recombinant Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Subunit
11.1.2.Live Attenuated
11.2.  Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Parenteral
11.2.2.Oral
11.3.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Human Papillomavirus
11.3.2.Hepatitis B
11.3.3.Rotavirus
11.3.4.Herpes Zoster
11.3.5.Meningococcal B
11.3.6.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Recombinant Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Subunit
12.1.2.Live Attenuated
12.2.  Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Parenteral
12.2.2.Oral
12.3.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Human Papillomavirus
12.3.2.Hepatitis B
12.3.3.Rotavirus
12.3.4.Herpes Zoster
12.3.5.Meningococcal B
12.3.6.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Recombinant Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Subunit
13.1.2.Live Attenuated
13.2.  Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Parenteral
13.2.2.Oral
13.3.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Human Papillomavirus
13.3.2.Hepatitis B
13.3.3.Rotavirus
13.3.4.Herpes Zoster
13.3.5.Meningococcal B
13.3.6.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Merck KGaA
14.2.2.Novartis AG
14.2.3.GlaxoSmithKline Plc.
14.2.4.GC Biopharma
14.2.5.Bayer AG
14.2.6.Sanofi SA
14.2.7.Pfizer Inc.
14.2.8.Bharat Biotech.
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Merck KGaA
  • Novartis AG
  • GlaxoSmithKline Plc.
  • GC Biopharma
  • Bayer AG
  • Sanofi SA
  • Pfizer Inc.
  • Bharat Biotech.

Related Industry Reports

Chronic Refractory Gout Pharmaceuticals Market

Familial Mediterranean Fever Pharmaceuticals Market

Australia Point of Care Diagnostics Market

Aseptic Sampling Market